{"disease":{"id":"soft-tissue-sarcoma","name":"soft tissue sarcoma"},"drugs":{"marketed":[{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Soft Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic soft tissue sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"yondelis","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yondelis","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"trabectedin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yondelis","generic_name":"TRABECTEDIN","company_name":"Janssen Prods","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src","drug_class":"Alkylating Drug [EPC]","quality_score":58,"revenue":null,"mechanism":"Yondelis works by binding to DNA and causing interstrand crosslinks, thereby inhibiting cancer cell growth."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic soft tissue sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"adriacin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"liposomal-doxorubicin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"hydroxydaunomycin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":11,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04181970","title":"Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Grupo Espanol de Investigacion en Sarcomas","has_results":false},{"nct_id":"NCT03244020","title":"LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology","phase":"PHASE4","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2868,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06526897","title":"Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1582,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT05697198","title":"PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine","phase":"","overall_status":"COMPLETED","enrollment_count":1429,"lead_sponsor_name":"Labcorp Corporation of America Holdings, Inc","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05171413","title":"Predictive Models of Treatment Responses and Survival Outcomes in Patients With Soft Tissue Sarcoma","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT07432932","title":"Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT03784014","title":"Molecular Profiling of Advanced Soft-tissue Sarcomas","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":603,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT00346164","title":"Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":588,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT01710176","title":"Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":550,"lead_sponsor_name":"Italian Sarcoma Group","has_results":false},{"nct_id":"NCT02451943","title":"A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":509,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT04671693","title":"A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT05328258","title":"Use of GnRHa During Chemotherapy for Fertility Protection","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Kenny Rodriguez-Wallberg","has_results":false},{"nct_id":"NCT00354835","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":481,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT01327885","title":"Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":452,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT06967961","title":"Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Institut Claudius Regaud","has_results":false},{"nct_id":"NCT06699576","title":"ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":448,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT05108298","title":"Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Eastern Cooperative Oncology Group","has_results":false},{"nct_id":"NCT02192333","title":"Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors","phase":"NA","overall_status":"COMPLETED","enrollment_count":390,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT03375437","title":"RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":376,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT06422806","title":"Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT05075993","title":"Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":352,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03452644","title":"US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Istituto Ortopedico Rizzoli","has_results":false},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT02659020","title":"A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":310,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT05739084","title":"Gene Signatures Searching of Sensitivity/Resistance to Neoadjuvant Radiotherapy in Patients With Resectable STS","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT05712694","title":"Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Polaris Group","has_results":false},{"nct_id":"NCT06797999","title":"First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"Adcendo ApS","has_results":false},{"nct_id":"NCT03138161","title":"SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Sarcoma Oncology Research Center, LLC","has_results":false},{"nct_id":"NCT02632448","title":"A Study of LY2880070 in Participants With Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"Esperas Pharma Inc.","has_results":false},{"nct_id":"NCT04751409","title":"Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":227,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00898755","title":"Collecting and Storing Tissue From Young Patients With Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT01574716","title":"Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":209,"lead_sponsor_name":"Morphotek","has_results":true},{"nct_id":"NCT04589741","title":"Toripalimab Combined With CAV/IE Regimen","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05955105","title":"A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Innolake Biopharm","has_results":false},{"nct_id":"NCT03277924","title":"Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Grupo Espanol de Investigacion en Sarcomas","has_results":false},{"nct_id":"NCT05146440","title":"Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":195,"lead_sponsor_name":"Grupo Espanol de Investigacion en Sarcomas","has_results":false},{"nct_id":"NCT00876031","title":"Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":195,"lead_sponsor_name":"University Hospital Tuebingen","has_results":false},{"nct_id":"NCT02379845","title":"NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Nanobiotix","has_results":false},{"nct_id":"NCT07261631","title":"Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02357810","title":"Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":178,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT04589754","title":"Adriamycin and Ifosfamide Combined With Sintilimab","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":176,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03997968","title":"A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"Cyteir Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04425967","title":"Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":168,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT04705818","title":"Combining Epigenetic And Immune Therapy to Beat Cancer.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT02500797","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04969835","title":"A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":158,"lead_sponsor_name":"Avacta Life Sciences Ltd","has_results":false},{"nct_id":"NCT01552434","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}